Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168591 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jeff Szer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Bone Marrow. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Apellis Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB.
Abstract (Originalsprache)
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, potentially life-threatening haematological disease characterised by chronic complement-mediated haemolysis with multiple clinical consequences that impair quality of life. This post hoc analysis assessed haematological and clinical responses to the first targeted complement C3 inhibitor pegcetacoplan in patients with PNH and impaired bone marrow function in the PEGASUS (NCT03500549) and PRINCE (NCT04085601) studies. For patients with impaired bone marrow function, defined herein as haemoglobin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia.
- Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany.
- Centre for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Düsseldorf (ABCD), 52074 Aachen, Germany.
- Department of Haematological Medicine, King's College Hospital, National Institute of Health Research/Wellcome King's Clinical Research Facility, London SE5 9RS, UK.
- Division of Hemtatology, Department of Apheresis Medicine, University of Alberta Hospital, University of Alberta, Edmonton, AB T6G 2B7, Canada.
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
ORCID-Profile: Jeff Szer, Monika Oliver, Bruno Fattizzo
Förderung
- Apellis Pharmaceuticals, Inc.
- Swedish Orphan Biovitrum AB
Zitieren
APA
Szer, J., Panse, J., Kulasekararaj, A., Oliver, M., Fattizzo, B., Nishimura, J. I., Horneff, R., Szamosi, J., & Peffault de Latour, R. (2024). Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168591
Vancouver
Szer J, Panse J, Kulasekararaj A, Oliver M, Fattizzo B, Nishimura JI, et al. Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168591
BibTeX
@article{Szer2024,
author = {Szer, Jeff and Panse, Jens and Kulasekararaj, Austin and Oliver, Monika and Fattizzo, Bruno and Nishimura, Jun-Ichi and Horneff, Regina and Szamosi, Johan and Peffault de Latour, Régis},
title = {Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168591}
}
EUVIMED